^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | BDTX-1535 (EGFR inhibitor, EGFR MasterKey inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3396 / 6 - Discovery of BDTX-1535, a novel 4th generation, irreversible, potent, wild type sparing EGFR MasterKey inhibitor that targets oncogenic kinase domain mutations as well as extracellular domain alterations for the treatment of NSCLC and GBM
Published date:
03/15/2023
Excerpt:
BDTX-1535 achieves potent anti-tumor activity against EGFR alterations and amplification across models including NSCLC and GBM PDX and intracranial tumors.
